

Onpattro™ (patisiran)



When requesting Onpattro™ (patisiran), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved indication

Onpattro is indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Coverage Guidelines

The individual must meet **ALL** of the following criteria for approval:

- Diagnosis of hereditary transthyretin-mediated amyloidosis is confirmed by genetic testing; AND
- Has symptomatic polyneuropathy (e.g., reduced motor strength/ coordination, impaired sensation [e.g., pain, temperature, vibration, touch]). Examples of assessments for symptomatic disease include history and clinical exam, electromyography, or nerve conduction velocity testing; AND
- Is at least 18 years of age; AND
- Has tried or is currently receiving at least one systemic agent for symptoms of polyneuropathy from one of the following pharmacological classes: a gabapentin-type product (e.g., gabapentin [Neurontin], pregabalin [Lyrica]), duloxetine (Cymbalta), or a tricyclic antidepressant (e.g., amitriptyline, nortriptyline); AND
- Onpattro is prescribed by or in consultation with a neurologist, geneticist, or a physician who specializes in the treatment of amyloidosis; AND
- There is no history of liver transplantation.

Approval duration: 12 months

Dosing Recommendations

- 0.3mg/kg IV is administered as an IV infusion once every 3 weeks (maximum dose 30mg)

References

1. Onpattro lipid complex injection, for intravenous use [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; February 2020.
2. Rizk M, Tüzmen Ş. Update on the clinical utility of an RNA interference-based treatment: focus on patisiran. *Pharmgenomics Pers Med*. 2017;10:267-278.
3. Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. *Curr Opin Neurol*. 2016;29 Suppl 1:S14-26.
4. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. *J Am Coll Cardiol*. 2015;66(21):2451-2466.
5. Ando Y, Coelho T, Berk JL. Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis*. 2013;8:31.
6. Kristen AV, Ajroud-Driss S, Conceição I, et al. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. *Neurodegener Dis Manag*. 2019;9(1):5-23.
7. Lin H, Merkel M, Hale C, Marantz JL. Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis. *Neurodegener Dis Manag*. 2020;10(5):289-300.